hc1 uses advanced data management, analytics, workflow automation and AI to turn diagnostic lab data into actionable insights that improve diagnoses and operational performance. The company completed an acquisition of healthcare performance consulting firm Accumen in October 2024 and markets the combined hc1 + Accumen platform. According to the release, thousands of health systems and labs leverage its technology and consultative services to care for nearly 100 million patients, and the company has over a decade of experience. The $6.25 million financing announced in January 2025 will support launching enhanced solutions that couple hc1 and Accumen’s technology and expertise. Product and operational priorities highlighted include lab stewardship, optimizing blood management and anemia care, eliminating supply chain waste, and improving lab outreach to drive profitable growth for health systems. The company positions these initiatives as advancing predictive insights, personalized care, and increased efficiencies across the care continuum. hc1.com provides a HIPAA-compliant healthcare CRM and analytics platform certified as an AWS Healthcare Competency solution. Its platform has been adopted across more than 1,200 lab, post-acute care, and provider locations and has organized over 5.2 billion clinical transactions into 52 million unique anonymous consumer profiles. The company offers information services including hc1 ProviderView™ and the hc1 Opioid Dashboard to drive personalized, high-value care and provider engagement. hc1 has been recognized as a top-rated healthcare CRM by Frost & Sullivan and counts organizations such as Cleveland Clinic and Nationwide Children’s Hospital among users. The company plans to accelerate development of its healthcare relationship management solutions, expand its team, and increase adoption of its information services. HC1 provides a scalable, cloud-based platform that ingests clinical and business data to help labs, pharmacies, physicians and health systems track business relationships and improve patient engagement. Its product is used to prompt follow-up actions (for example, identifying why a patient missed an appointment) and to coordinate multiparty communication across care teams. The company sees large near-term opportunities in diagnostics and potential future uses including aiding therapeutic discovery and identifying specimen errors. HC1 partners with technology providers such as IBM Watson to generate patient insights and reduce administrative burden through AI-powered tools. Its business model charges customers based on usage, and management plans to expand direct sales and strategic partnerships while adding sales and marketing staff. Financially, HC1 recently raised capital and credit to support this growth push, including a $13.2M financing and a $5M revolving credit facility.

Total raised

$31M

Funding rounds

4

Latest round

Equity

Latest activity

Jan 2025